oncology

Showing 15 posts of 322 posts found.

dr_paolo_paoletti

PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board

January 7, 2016
Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology

Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …

melanoma cell

100 year old chemical could be the future of cancer treatment

December 23, 2015
Research and Development Cancer, PV-10, Peter Culpepper, Provectus, Rose Bengal, oncology

Peter Culpepper, chief operating officer at Provectus Biopharmaceuticals, explains the secrets of Rose Bengal, which has impressed in clinical trials …

R&D researcher

More breakthroughs in cancer pose the question: Who pays for them?

December 16, 2015
Research and Development Cancer, drug access, immunotherapy, oncology

The molecular revolution over the last decade has done much to help turn cancer into an illness that can be …

Merck researcher

Merck/Pfizer Alliance to collaborate on late-stage cancer trials

December 10, 2015
Research and Development Merck, Pfizer, avelumab, collaboration, gastric cancer, oncology, partnership, stomach cancer

Merck and Pfizer are partnering to run two Phase III trials of avelumab, an immuno-oncology treatment the companies hope to …

Red blood cells

ASH 2015 roundup: Amgen, MorphoSys, Novartis and Roche present new trial data

December 8, 2015
Research and Development Amgen, Cancer, Novartis, Roche, ash, morphosys, oncology

Amgen Amgen presented data from three Phase II trials evaluating Blincyto (blinatumomab) in acute lymphoblastic leukemia (ALL)- a rare and …

janssen_latest_logo_on_sign_closer

Strong cancer trial data for Janssen at ASH 2015

December 8, 2015
Research and Development Cancer, Janssen, darzalex, imbruvica, oncology

Janssen presented new cancer trial data at the 57th Annual American Society of Haematology (ASH) meeting Orlando, Florida – with …

Takeda reveals five-year Adcetris survival data

December 6, 2015
Research and Development, Sales and Marketing Hodgkin lymphoma, Takeda, oncology

Takeda UK has announced post-treatment follow up data from the pivotal Phase II study of Adcetris revealing a five-year survival …

zometa

Cancer drugs prices vary up to 388% between high-income countries

December 4, 2015
Medical Communications, Sales and Marketing Cancer, Drug pricing, Eli Lilly, Genzyme, Lancet, Novartis, oncology

The price of new cancer drugs varies widely between high-income countries in Europe, Australia, and New Zealand, new research published …

Clinigen logo

Clinigen launches UK managed access program for Takeda’s ixazomib

November 30, 2015
Sales and Marketing Clinigen, Takeda, ixazomib, managed access, multiple myeloma, oncology

Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib …

ASH 2014 meeting

Bayer and Novartis to debut new data at ASH 2015

November 30, 2015
Research and Development, Sales and Marketing American Society of Hematology, Bayer, Conference, Novartis, ash, clinical trials, haematology, oncology

Pharma firms will present clinical trial results for the pipeline drugs they are pinning their 2016 hopes for success on, …

Chest x ray

Lilly cancer drug gets US approval

November 26, 2015
NSCLC, Portrazza, lilly, lung cancer, necitumumab, non-small cell lung cancer, oncology

Eli Lilly has received FDA approval for its monoclonal antibody Portrazza, in combination with gemcitabine and cisplatin, for patients with …

Takeda oncology

Challenges in oncology R&D – part 2

November 25, 2015
Manufacturing and Production, Research and Development R&D, Takeda, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Takeda oncology

Challenges in oncology R&D

November 18, 2015
Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology

Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …

Merck R&D

Merck and Selvita form oncology partnership

November 2, 2015
Research and Development, Sales and Marketing Merck, Selvita, collaboration, oncology

Merck has entered a three-year agreement with Selvita to validate new therapeutic concepts in the field of oncology. The aim …

Counting the true cost of the Cancer Drugs Fund cuts

September 14, 2015
Research and Development Cancer, Cancer Drugs Fund, NHS, clinical trials, cuts, oncology

Leading figures from the pharma industry and cancer charities reacted with dismay to the recent cuts to the Cancer Drugs …

The Gateway to Local Adoption Series

Latest content